Indivior PharmaceuticalsINDV -1.34%69 PE Ratio (TTM) is 21.16 as of Jun. 30, 2026, which is 16% above its 10-year median of 18.18. GuruFocus rates INDV with a GF Score™ of 69/100 and a GF Value™ of $22.98 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 635 Drug Manufacturers companies, Indivior Pharmaceuticals ranks worse than 51.34% on this metric.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-06-30), Indivior Pharmaceuticals's share price is
$41.26.
Indivior Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $1.95. Therefore, Indivior Pharmaceuticals's PE Ratio (TTM) for today is 21.16.
The historical rank and industry rank for Indivior Pharmaceuticals's PE Ratio (TTM) or its related term are showing as below:
INDV'
s PE Ratio (TTM) Range Over the Past 10 Years
Min: 1.46 Med: 18.18 Max: 179.92
Current: 21.16
During the past 13 years, the highest PE Ratio (TTM) of Indivior Pharmaceuticals was 179.92. The lowest was 1.46. And the median was 18.18.
INDV's PE Ratio (TTM) is ranked worse than 51.34% of 635
companies
in the Drug Manufacturers industry
Industry Median: 20.28
vs INDV: 21.16
During the past 12 months, Indivior Pharmaceuticals's average EPS without NRIGrowth Rate was 99.30% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 29.20% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 37.90% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 0.30% per year.
During the past 13 years, Indivior Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 57.70% per year. The lowest was -39.40% per year. And the median was -11.80% per year.
Indivior Pharmaceuticals (NAS:INDV) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
Indivior Pharmaceuticals PE Ratio (TTM) Related Terms
Indivior Pharmaceuticals PE Ratio (TTM) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INDV vs KNSA, AMRX, RGC: PE Ratio (TTM) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Indivior Pharmaceuticals's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indivior Pharmaceuticals PE Ratio (TTM) vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Indivior Pharmaceuticals's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where Indivior Pharmaceuticals's PE Ratio (TTM) falls into.
Indivior Pharmaceuticals PE Ratio (TTM) Calculation
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
Indivior Pharmaceuticals's Share Price of today is $41.26.
Indivior Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.95.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Indivior Pharmaceuticals (INDV) has a PE Ratio (TTM) of 21.16 as of Jun. 30, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Indivior Pharmaceuticals and its competitors. This is 16% above median its historical median of 18.18. Over the past decade, Indivior Pharmaceuticals' PE Ratio (TTM) has ranged from 1.46 to 179.92. According to the industry distribution chart, Indivior Pharmaceuticals ranks #326 out of 635 companies in the Drug Manufacturers industry, placing it in the top 51.3%.
Is Indivior Pharmaceuticals' PE Ratio (TTM) too high?
Indivior Pharmaceuticals' current PE Ratio (TTM) of 21.16 is 16% above median its 10-year median of 18.18. Over the past 10 years, this metric has ranged from a low of 1.46 to a high of 179.92. The Drug Manufacturers industry median PE Ratio (TTM) is 20.28. Indivior Pharmaceuticals' value of 21.16 is 4.3% above this industry median. Based on the distribution chart, Indivior Pharmaceuticals ranks #326 out of 635 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Indivior Pharmaceuticals has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Indivior Pharmaceuticals' PE Ratio (TTM) compare to KNSA and AMRX?
According to the Drug Manufacturers industry distribution chart, Indivior Pharmaceuticals ranks #326 out of 635 companies for PE Ratio (TTM). This places Indivior Pharmaceuticals in the lower half of its industry. The industry median PE Ratio (TTM) is 20.28. Indivior Pharmaceuticals' value of 21.16 is 4.3% above this benchmark. Historically, Indivior Pharmaceuticals' own PE Ratio (TTM) has ranged from 1.46 to 179.92 over the past decade. While the company's 10-year median is 18.18 vs. the industry median of 20.28, Indivior Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Drug Manufacturers company?
The median PE Ratio (TTM) among Drug Manufacturers companies is 20.28, based on 635 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Indivior Pharmaceuticals's current PE Ratio (TTM) of 21.16 is 4.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Indivior Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median PE Ratio (TTM) is 20.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indivior Pharmaceuticals's current PE Ratio (TTM) is 21.16, which is 16% above median its own 10-year median of 18.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indivior Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Indivior Pharmaceuticals (INDV) is currently considered Significantly Overvalued. The stock's GF Value™ is $22.98, compared to a current price of $41.26 — trading 79.5% above its estimated fair value. The current PE Ratio (TTM) is 21.16, which is 16% above median its 10-year median of 18.18 and 4.3% above the Drug Manufacturers industry median of 20.28. Indivior Pharmaceuticals' overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For Indivior Pharmaceuticals (INDV), the current PE Ratio (TTM) is 21.16 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Indivior Pharmaceuticals (INDV) Overvalued in 2026?
Based on GuruFocus' analysis, Indivior Pharmaceuticals stock appears to be overvalued.
The current stock price of $41.26 is trading 79.5% above its estimated GF Value™ of $22.98.
GuruFocus considers Indivior Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for INDV:
PE Ratio (TTM): 21.16 (16% above median its 10-year median of 18.18)
GF Value™: $22.98 vs. price of $41.26 (79.5% above fair value)
Industry Position: 4.3% above the Drug Manufacturers median (#326 of 635)
No single metric tells the full story. See the INDV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
69GF Score
Get the complete analysis for INDV
PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INDV has been successfully added to your 
